Role of CD30 targeting in malignant lymphoma Journal Article

  


Authors: Kumar, A.; Younes, A.
Article Title: Role of CD30 targeting in malignant lymphoma
Abstract: CD30 is an important therapeutic target for the treatment of malignant lymphomas. CD30 is a member of the TNF cell receptor superfamily and is highly expressed in a variety of lymphoma subsets, including Hodgkin lymphoma and anaplastic large cell lymphoma. Initial studies evaluated the safety and efficacy of several monoclonal antibodies targeting CD30, with limited success. More recently, the anti-CD30 drug-conjugate brentuximab vedotin produced high response rates with an excellent safety profile. These results lead to the approval of brentuximab vedotin for the treatment of patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma. Current studies are focusing on incorporating brentuximab vedotin in front-line regimens and expanding its potential clinical utility in other CD30-expressing malignancies. © 2014 Springer Science+Business Media.
Keywords: unclassified drug; drug tolerability; fatigue; neutropenia; paresthesia; doxorubicin; placebo; diarrhea; drug efficacy; drug potentiation; drug safety; drug withdrawal; drug approval; drug targeting; gemcitabine; methotrexate; antigen expression; dacarbazine; melanoma; multiple cycle treatment; anemia; nausea; thrombocytopenia; peripheral neuropathy; bendamustine; antineoplastic activity; structure activity relation; vinblastine; hodgkin disease; monoclonal antibody; temsirolimus; drug dose escalation; febrile neutropenia; hyperglycemia; pneumonia; tumor lysis syndrome; cutaneous t cell lymphoma; peripheral t cell lymphoma; t cell lymphoma; nonhodgkin lymphoma; drug distribution; pancreatitis; drug response; lymphoma; radiopharmaceutical agent; bleomycin; progressive multifocal leukoencephalopathy; virus infection; large cell lymphoma; drug half life; navelbine; alopecia; germ cell tumor; mycosis fungoides; hodgkin lymphoma; stevens johnson syndrome; history of medicine; cd30 antigen; motor neuropathy; skin lymphoma; systemic mastocytosis; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); sgn 30; bexarotene; anaplastic large cell lymphoma; antigen antibody reaction; skin tingling; lymphomatoid papulosis; antibody-drug conjugate; brentuximab vedotin; cd30; human; article; iratumumab; xmab 2513; monoclonal antibody afm13; monoclonal antibody cd30 i 131; monoclonal antibody xmab2513; mast cell leukemia
Journal Title: Current Treatment Options in Oncology
Volume: 15
Issue: 2
ISSN: 1527-2729
Publisher: Springer  
Date Published: 2014-06-01
Start Page: 210
End Page: 225
Language: English
DOI: 10.1007/s11864-014-0275-7
PROVIDER: scopus
PUBMED: 24570331
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84902361962&partnerID=40&md5=acc59a92781f537428543bb3ea503c61
Notes: Curr. Treat. Options Oncol. -- Export Date: 8 July 2014 -- CODEN: CTOOB -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Anita Kumar
    180 Kumar
  2. Anas Younes
    319 Younes
Related MSK Work